SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 28th, 2014 • Innovus Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This Securities Purchase Agreement (this “Agreement”) is dated as of February 13, 2014, between Innovus Pharmaceuticals, Inc., a Nevada corporation (the “Company”) and GEMINI MASTER FUND, LTD. a Cayman Islands Company (including its successors and assigns, “Purchaser”).
ContractInnovus Pharmaceuticals, Inc. • March 28th, 2014 • Pharmaceutical preparations • California
THIS 10% CONVERTIBLE DEBENTURE is a duly authorized and validly issued 10% Convertible Debenture of Innovus Pharmaceuticals, Inc., a Nevada corporation, (the “Company”), having its principal place of business at 9171 Towne Centre Drive, Suite 440, San Diego, CA 92122 designated as its 10% Convertible Debenture due 2015 (the “Debenture”).
Right to Purchase up to 250,000 Shares of Common Stock of Innovus Pharmaceuticals, Inc. (subject to adjustment as provided herein) COMMON STOCK PURCHASE WARRANTInnovus Pharmaceuticals, Inc. • March 28th, 2014 • Pharmaceutical preparations • California
This Warrant has been issued pursuant to the terms of that certain Securities Purchase Agreement, dated as of February 13, 2014 (the “Purchase Agreement”), by and among the Company and Purchaser party thereto, including the Holder. Capitalized terms not defined herein shall have the meanings given to them in the Purchase Agreement. As used herein the following terms, unless the context otherwise requires, have the following respective meanings:
Henry EsberInnovus Pharmaceuticals, Inc. • March 28th, 2014 • Pharmaceutical preparations
Re: Amended and Restated 8% Convertible Debenture Conversion Letter AgreementInnovus Pharmaceuticals, Inc. • March 28th, 2014 • Pharmaceutical preparations
We are offering holders of the Innovus Pharmaceuticals, Inc. (“Innovus” or the “Company”) Amended and Restated 8% Convertible Debenture, dated November 11, 2013 (the “Debenture”), with the opportunity to do a one-time conversion of the outstanding principal and interest under the Debenture at a conversion rate of $0.40 per share of common stock of the Company.
INNOVUS PHARMACEUTICALS, INC. AMENDMENT TO SECOND AMENDED AND RESTATED 8% CONVERTIBLE DEBENTUTREInnovus Pharmaceuticals, Inc. • March 28th, 2014 • Pharmaceutical preparations
THIS AMENDMENT TO SECOND AMENDED AND RESTATED 8% CONVERTIBLE DEBENTURE (“Amendment”) is entered into as of February 19, 2014 (the “Effective Date’), by and among Innovus Pharmaceuticals, Inc., a Nevada corporation (“Issuer”), and Bassam Damaj (“Debenture Holder”).
